29 C
Vientiane
Monday, June 9, 2025
spot_img
Home Blog Page 1524

Pecan Energies, operator of Deepwater Tano/Cape Three Points (DWT/CTP) block, completes rebranding, committing to unlock prosperity for Ghana and beyond


ACCRA, GHANA – EQS Newswire – 4 March 2024 – Pecan Energies (www.PecanEnergies.com), the operator of the Deepwater Tano/Cape Three Points (DWT/CTP) block offshore Ghana is thrilled to announce the successful completion of its rebranding journey.

The company has evolved with a new name, logo, and a revitalized brand identity to better reflect its commitment to building prosperity and enabling growth for African communities. Underlining this transformation is Pecan Energies’ new tagline: “Unlocking Prosperity.”

Africa Finance Corporation (AFC) acquired Pecan Energies in April 2023, laying the foundations for a new brand identity. AFC is a multilateral financial institution created by African sovereign states to provide pragmatic solutions to Africa’s infrastructure deficit and challenging operating environment. The acquisition was a demonstration of AFC’s commitment to ensure that Africa’s natural resources, including its vast oil and gas reserves, are developed sustainably while retaining value on the continent. Pecan Energies holds a 50 per cent stake in the DWT/CTP block offshore Ghana.

“Pecan Energies represents our ambition to become the Pan-African oil and gas operator of choice in offshore deep waters of Ghana. Our new brand is dedicated to value creation, one of our core values. This also includes an unwavering commitment to transparency in how we harness our commercial and technical expertise for developmental outcomes in Ghana and beyond,” said Eiliv Gjesdal, Chief Executive Officer of Pecan Energies AS.

Pecan Energies is making good progress towards a Final Investment Decision (FID) following the successful approval of its Plan of Development (PoD) for the DWT/CTP contract area by Ghanaian authorities. Under its new ownership and identity, the goal is to realize the full social and economic impact potential of the entire DWT/CTP block. The block has discoveries of approximately 550 million barrels of recoverable oil equivalents, in addition to a significant exploration portfolio.

“As we embrace our new identity, sustainability, localization, empowerment, and giving back aren’t just commitments — they’re woven into the very fabric of our business,” said Kadijah Amoah, Chief Executive Officer of Pecan Energies Ghana Limited.

Key Highlights of the Rebrand:

New Logo: The logo is a culmination of modern design elements that represent the company’s forward-thinking approach. It has been designed to be clear, simple, and bold and stems from a series of shapes and symbols that evoke collaboration and mutual benefit.

Brand Palette & Typography: Adopting a palette that represents our devotion to the sustainable development of the natural resource was essential and plays a central role in creating and sustaining brand recognition.

Vision and Mission: Our vision and mission speak to our aspiration to mature and produce resources in a safe, efficient, and environmentally responsible manner for the mutual benefit of the Ghanaian people, the company, and our partners. Our goal is to unlock greater prosperity in Ghana and beyond.

Download image: https://apo-opa.co/3IeRWH4 (Diversity and Sustainability)

Hashtag: #PecanEnergies

The issuer is solely responsible for the content of this announcement.

About Pecan Energies:

Pecan Energies is the operator and 50 per cent shareholder in the Deepwater Tano Cape Three Points block (DWT/CTP) offshore Ghana. It is fully owned by Africa Finance Corporation. Our partners in the DWT/CTP block are: Lukoil Overseas Ghana Tano Limited, 38 per cent, Fueltrade Limited 2% and the Ghana National Petroleum Corporation, 10%.

Read more about Pecan Energies at

Focused on positive impact: Ricola becomes a B Corporation


LAUFEN, SWITZERLAND – Newsaktuell – 4 March 2024 – Marking an important milestone on its sustainability journey, Ricola is now a certified B Corporation™. This step reflects Ricola’s long-standing commitment to environmental stewardship and social responsibility, in line with its values as a family-owned enterprise.

Focused on positive impact: Ricola becomes a B Corporation

As B Corporation, Ricola has been verified as meeting non-profit organization B Lab’s high standards in the areas of social and environmental impact, legal commitment to responsible company practices and public transparency.

Responsibility and sustainability are in the nature of Ricola

Ricola’s path to becoming a B Corporation is built on a foundation laid at the company’s inception, namely its respect for the Swiss Alpine ecosystems that produce the herbs for its products. Ricola has long understood sustainability as a core business principle. The company’s practices, from herb cultivation according to organic standards to continuously striving towards environmentally sound product manufacturing, are designed to preserve and nurture these ecosystems and their biodiversity, ensuring a positive impact on the environment and society.

Focused on positive impact: Ricola becomes a B Corporation

“We owe everything to nature. Becoming a B Corporation aligns with our identity as a family-owned company and our dedication to connecting people with nature,” says Thomas P. Meier, CEO of Ricola. “It’s about balancing our ambitions for growth with our responsibilities to the planet and its people.”

“B Lab Switzerland Foundation is truly honored to welcome Ricola into the B Corp movement. As an iconic Swiss company with nearly a century of unwavering commitment to nature and communities, Ricola embodies the principles of using business as a force for good. Their dedication to resiliency and sustainability leadership is exemplary,” says Jonathan Normand, Founder and CEO of B Lab Switzerland.

A framework for action: Ricola’s sustainability strategy

Over the past two years, Ricola has refined a comprehensive approach to sustainability, identifying six core areas where it can have the most significant impact: agriculture principles, waste management, packaging innovation, climate change mitigation, water conservation, and ethical sourcing.

For each area, Ricola has set quantitative targets and implements annual “footsteps” – actionable steps to achieve these targets. These efforts are managed across the Ricola Group, with each part of the company playing a role on the collective journey towards sustainability.

As a B Corporation, Ricola is required to meet rigorous standards of social and environmental performance, which includes continuous improvements towards recertification every three years, to ensure compliance and progress. Ricola has committed to evaluating its sustainability performance using globally recognized key figures. It plans to report on its progress biennially according to the Global Reporting Initiative (GRI) guidelines, which are applied by a multitude of companies worldwide. The initial report for 2022 is available for download on the company’s website.

– Picture is available at AP

The issuer is solely responsible for the content of this announcement.

Ricola – Company Profile

Ricola is one of the world’s most modern and innovative manufacturers of herb drops. Ricola herb specialties are exported to 45 countries and are famous for their fine Swiss quality. Founded in 1930, with headquarters in Laufen near Basel and subsidiaries in Europe, Asia and the USA, Ricola now produces around 50 different herb drops and tea specialties. In Switzerland, this family-owned company is a pioneer in herb cultivation and places great value on using carefully selected locations and controlled, environmentally sound cultivation methods. Ricola has concluded fixed long-term purchase agreements with around 85 farmers in Swiss mountain regions. As a certified B Corporation, Ricola is committed to sustainable corporate management, economically, socially and ecologically and is a responsible employer. The traditional values of a family enterprise coupled with Swiss quality and a passion for innovation are crucial factors in the success of the Ricola global brand.

About B Lab™

B Lab is the nonprofit network transforming the global economy to benefit all people, communities, and the planet. B Lab creates standards, policies, tools, and programs that shift the behavior, culture, and structure of capitalism. We mobilize the global B Corp community towards collective action to address society’s most critical challenges, and we collaborate with governments, academia, coalitions, and other institutions to drive economic systems change.

About Certified B Corporation™

Certified B Corporations, or B Corps, are companies verified by B Lab to meet high standards of social and environmental performance, transparency, and accountability.

Berlin Cures’ BC 007 Targeting Long COVID Achieves Solid Progress with Over 50% Patient Recruitment in Phase II Trial

  • Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.
  • Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases.

BERLIN, GERMANY – Media OutReach Newswire – 4 March 2024 – Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria. The trial is investigating the efficacy of BC 007, the company’s pioneering drug candidate designed to neutralize functional autoantibodies (fAABs), which play a key role in the persistence of Long COVID symptoms.

BC 007

The study is actively progressing across 12 trial centers in Finland, Germany, Austria, Switzerland, and Spain, exemplifying the collaborative effort to address Long COVID, which has developed into a significant global health issue. Progress is strong and another seven centers are set to join soon. Anticipated results in autumn 2024 will pave the way for the next development stage, with Berlin Cures currently seeking additional funding to complete Phase II and initiate the crucial Phase III study necessary for regulatory approval.

“Long COVID is a global health crisis, negatively impacting over 100 million people worldwide, significantly reducing their quality of life and imposing substantial economic and social burdens. It puts immense pressure on our health systems and strains economic resources,” states Oliver von Stein, CEO of Berlin Cures. “If we don’t act now, we face spiraling healthcare costs, lost productivity, and widening social gaps. Our united front of clinical centers across Europe marks a pivotal move in confronting the pressing issue of Long COVID.”

Dr Oliver von Stein
Dr Oliver von Stein

As a biotech company focused on neutralizing fAABs, Berlin Cures stands at the forefront of developing innovative treatments for a variety of autoimmune diseases, including Long COVID, heart failure, glaucoma, and many others. Its drug candidate, BC 007, represents a promising solution by targeting harmful fAABs implicated in a range of autoimmune conditions such as Long COVID.

The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug’s effectiveness and safety for patients. The company anticipates a positive outcome, which will pave the way to proceed with a larger Phase III study, crucial for BC 007’s approval.

BC 007 Could Potentially Cure Long COVID for Many
Current estimates indicate that functional autoantibodies (fAABs) are detectable in blood tests in about 40% of all Long COVID patients. Functional autoantibodies are a specific type of autoantibody that can develop as an immune response following infections, mistakenly target the body’s tissues or cells. This interaction can lead to autoimmune diseases. Unlike normal antibodies that protect against infections, fAABs disrupt normal functions by binding to cell receptors or other proteins, often imitating or blocking natural signals needed for healthy cell functions. This disruption can result in a variety of autoimmune diseases, depending on the target of the autoantibodies and the role of the targeted tissue in the body.

“The presence of fAABs in such a large portion of patients highlights the potential of BC 007 to combat the underlying cause of Long COVID symptoms in a significant group of affected individuals. We are convinced of BC 007’s therapeutic potential and are actively seeking support to prepare for a larger Phase III study,” adds Oliver von Stein. “Our commitment to finding a cure for diseases caused by fAABs remains steadfast, supported by private funding since our inception.”

Versatile Platform Technology Targeting Multiple Medical Conditions
The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

Built on more than two decades of fAAB-research, Berlin Cures has advanced BC 007 into clinical trials. This journey has demonstrated efficacy in Phase I studies with fAAB-positive volunteers and in a Phase IIa trial with heart failure patients, showing significant long-term benefits. Preclinical and clinical results with BC 007 have shown effective and lasting neutralization of fAABs after treatment. Moreover, BC 007 has proven to be safe and well-tolerated. With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

Hashtag: #BerlinCures

The issuer is solely responsible for the content of this announcement.

About Berlin Cures:

The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. It was found effective in fAAB-positive healthy volunteers during the Phase I study and in heart failure patients in a Phase IIa trial, where it demonstrated long-term autoantibody neutralization after a single dose and significant improvement in cardiac function, with no spontaneous disappearance of autoantibodies in untreated patients. Its potential against Long COVID is indicated by lab data generated using sera from Long COVID patients, and four case studies. By tackling the root cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core.

Since June 2023, Berlin Cures has been absolving a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability of BC 007 with patients suffering from Long COVID.

Heng An Standard Life (Asia) fully supports Hong Kong new Capital Investment Entrant Scheme with ILAS now available for application

Celebrating our 25 years by introducing the “5N Proposition” to provide customers with comprehensive long-term insurance and wealth management services


HONG KONG SAR – Media OutReach Newswire – 4 March 2024 – Heng An Standard Life (Asia) Limited (“HASL Asia” or “the Company”) welcomes and fully supports Hong Kong new Capital Investment Entrant Scheme (CIES). The company is committed to tying in with government policies to improve Hong Kong’s competitive advantages in wealth management. As part of its 25th anniversary celebrations, the company is pleased to introduce the “5N Proposition” that offers customers with comprehensive long-term insurance and wealth management services. It encompasses the New CIES Proposition, New Products, New Investment Choices, New Fund Houses, and a New Platform. This comprehensive initiative comes in response to the strong market demand and aims to enhance customers’ wealth planning.

Olivia Liu, Chief Executive of HASL Asia, welcomes and fully supports the new CIES introduced in Hong Kong to enhance the city's competitive advantage in wealth management. In celebration of the company's 25th anniversary, we are proud to introduce the “5N Proposition” in response to customer demand, further strengthening our position as a leading wealth-focused insurance company in Hong Kong.
Olivia Liu, Chief Executive of HASL Asia, welcomes and fully supports the new CIES introduced in Hong Kong to enhance the city’s competitive advantage in wealth management. In celebration of the company’s 25th anniversary, we are proud to introduce the “5N Proposition” in response to customer demand, further strengthening our position as a leading wealth-focused insurance company in Hong Kong.

New CIES Proposition: As the insurance company offering the most extensive selection of investment choices in the investment-linked assurance scheme (ILAS) market*, HASL Asia provides diversified investment choices to attract asset owners to settle in Hong Kong under the expanded CIES. The company’s ILAS is open now for application under the new CIES.

New Products: Introducing a new Protection-Linked Plan (PLP), which offers customers higher life protection compared to traditional ILAS products, while also addressing their investment needs. With increased life protection coverage available before the age of 65, along with a transparent fee structure and regulated investment options, PLP aims to address gaps in protection. Additionally, the PLP offers customers at least one Environment, Social, and Governance (ESG) investment option approved by the Securities and Futures Commission, promoting greater awareness of and participation in ESG investing.

New Fund Houses: Expanding the number of fund providers on our investment platform to 25, widening the range of investment options. The three new fund providers include China Universal Asset Management (Hong Kong) Company Limited, Da Cheng International Asset Management Company Limited, and E Fund Management (Hong Kong) Company Limited.

New Investment Choices: Adding up to 15 income-distribution investment choices to our ILAS, including currency market and balanced investment choices provided by the new fund houses. This brings the total number of investment choices to over 300, cementing the company’s position as the insurance company with the most diverse investment choices in the Hong Kong ILAS market*.

New Platform: Introducing the innovative online investment portfolio platform “In+” to facilitate convenient management of ILAS policies’ investment portfolios for customers and financial advisers. In addition, financial advisers will be invited to participate in a simulated investment game on In+, with prizes as incentive. Further details will be announced soon.

Olivia Liu, Chief Executive of HASL Asia, said: “HASL Asia welcomes and fully supports the new Capital Investment Entrant Scheme in Hong Kong, and we will actively tie in with government policies to enhance the development advantages of wealth management in Hong Kong, attracting more investors to settle in the city. We are honoured to embark on our 25th year together with our valued customers and business partners. As we step into this new era, we are excited to introduce the ‘5N Proposition’, providing our customers with comprehensive long-term insurance and wealth management services. Additionally, we will continue organising training activities in collaboration with various institutions through our MoreAcademy, enabling our colleagues and business partners to sharpen their expertise in financial planning. We are dedicated to contributing to the long-term development of the industry, living up to our brand belief of ‘Get more from life’, and remaining committed to becoming a leading, wealth-focused insurance company in Hong Kong.”

*As of 1 March 2024

For information about HASL Asia and its products, please visit our company website: https://www.hengansl.com.hk

For details about the new CIES, please visit the website of InvestHK: https://www.newcies.gov.hk/en/resources/apply-now.html

Hashtag: #HengAnStandardLifeAsia #HASLA #WealthManagement #Insurance #CIES #5N #NewCIESProposition #NewProduct #NewInvestmentChoices #NewFundHouses #NewPlatform #PLP #MoreAcademy #25thAnniversary #HongKong #In+ #ILAS #Finance #Wealth #ESG




The issuer is solely responsible for the content of this announcement.

HPV Affects Us All – Be Protected and Make It #OneLessWorry


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 4 March 2024 – Human papillomavirus (HPV) is the primary cause of cervical cancer. Despite being a preventable disease, cervical cancer ranks as the 4th most frequent cancer among women and the second most frequent cancer among women aged 15 to 44 in Malaysia[i]. In conjunction with the International HPV Awareness Day 2024 campaign led by the International Papillomavirus Society (IPVS), GSK is also committed to take a stand against HPV in Malaysia through collaborative efforts with various stakeholders.

International HPV awareness calls for the public to be educated about the infection and its associated cancers, which can be prevented through screening and vaccination, making it ‘One Less Worry’ for the world.

Dr. Alap Gandhi, Country Medical Director of GSK Malaysia said “Malaysia’s commitment to eliminating cervical cancer through its proactive pioneering initiatives are exemplary in the fight against this preventable disease. Since 2010, GSK has demonstrated its commitment to take a stand against HPV in Malaysia.”

Professor Dr. Jamiyah Hassan, Senior Consultant in O&G and Feto-Maternal Medicine, Hospital Al-Sultan Abdullah, UiTM Puncak Alam, Faculty of Medicine, UiTM Sg Buloh Campus said “Cervical cancer is the fourth most common cancer among women in Malaysia, and WHO has called for a global reduction of cervical cancer by 2030 to below 4 per 100,000 women. Cervical cancer has a clear causation from the Human Papilloma Virus. With effective means for HPV prevention and a sensitive HPV screening test, cervical cancer stands out as a highly preventable disease. Regular screening of the cervix for HPV infections is crucial for early detection of precancerous disease to allow early treatment to stop progression to advanced stages. Women must be empowered to take charge of their health and make informed choices about their well-being.”

What is HPV?

HPV is a group of viruses commonly related to sexually transmitted infection (STI). As there are over 150 HPV strains, everyone will become infected at some point in their lives, often without being aware of it. While most infections aren’t harmful and typically resolve over time as the immune system controls the infection, some strains of HPV can cause health conditions, including skin warts on the hands, feet, and genitals, or even cancer if left untreated.

Who is at Risk?

Women who become sexually active at a young age, especially before age 18, or have multiple sexual partners are more likely to become infected with a high-risk type of HPV.

How to Stay Protected?

The development of cervical cancer from HPV infection typically follows a prolonged timeline often spanning between 10 to 15 years. Regular screenings and early detection play a crucial role in managing and preventing mutation of cells. Pap smears are recommended for women between the age of 21 to 29 yearly for 2 years and then every three years. Following that, individuals up to the age of 65 should screen once every five years.

If HPV is detected during the tests or screening, specialists or pathologists will then use the same sample to assess the presence of abnormal cells. In cases where no abnormal cell changes are identified, patients will be advised to undergo a follow-up test after 12 months to monitor the presence of the virus.

Doing so would allow HPV to truly be #OneLessWorry and bring the world to be one step closer in achieving the World Health Organization’s 90-70-90 targets where 90% of girls are fully vaccinated with HPV vaccine by age 15 years; 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age; and 90% of women identified with cervical disease receive treatment by 2030[ii].

By staying ahead of the curve through vaccines, specialty, and general medicines, GSK hopes to continue to play a part in the betterment of public health in Malaysia.


[i] Data from The Catalan Institute of Oncology (ICO) and the International Agency for Research on Cancer (IARC) Report 2023

[ii] Cervical cancer elimination initiative by the World Health Organisation

Hashtag: #OneLessWorry #GSK

The issuer is solely responsible for the content of this announcement.

GSK

GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We have been operating in Malaysia for over 65 years, since starting our first operations in October 1958. In the last six decades, GSK Malaysia has grown substantially both in its infrastructure, business operations as well as talent base. Currently operating with over 400 employees spread across our two business entities – Pharmaceuticals & Vaccines and Business Service Centre. Find out more at .

Berlin Cures’ BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

  • Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.
  • Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases.

BERLIN, GERMANY – Media OutReach Newswire – 4 March 2024 – Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria. The trial is investigating the efficacy of BC 007, the company’s pioneering drug candidate designed to neutralize functional autoantibodies (fAABs), which play a key role in the persistence of Long COVID symptoms.

BC 007
BC 007

The study is actively progressing across 12 trial centers in Finland, Germany, Austria, Switzerland, and Spain, exemplifying the collaborative effort to address Long COVID, which has developed into a significant global health issue. Progress is strong and another seven centers are set to join soon. Anticipated results in autumn 2024 will pave the way for the next development stage, with Berlin Cures currently seeking additional funding to complete Phase II and initiate the crucial Phase III study necessary for regulatory approval.

“Long COVID has impacted the lives of over 100 million people globally, altering the day-to-day existence of countless individuals,” states Oliver von Stein, CEO of Berlin Cures. “Our mission with BC 007 is not just to treat a virus’s lingering effects but to restore the quality of life for those affected. By harnessing the power of innovative science, we are on the cusp of a breakthrough that could return health and vitality to millions. The progress of our clinical trial across Europe is a beacon of hope and a testament to what we can achieve through collaboration and dedication.”

Dr Oliver von Stein
Dr Oliver von Stein

As a biotech company focused on neutralizing fAABs, Berlin Cures stands at the forefront of developing innovative treatments for a variety of autoimmune diseases, including Long COVID, heart failure, glaucoma, and many others. Its drug candidate, BC 007, represents a promising solution by targeting harmful fAABs implicated in a range of autoimmune conditions such as Long COVID.

The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug’s effectiveness and safety for patients. The company anticipates a positive outcome, which will pave the way to proceed with a larger Phase III study, crucial for BC 007’s approval.

BC 007 Could Potentially Cure Long COVID for Many
Current estimates indicate that functional autoantibodies (fAABs) are detectable in blood tests in about 40% of all Long COVID patients. Functional autoantibodies are a specific type of autoantibody that can develop as an immune response following infections, mistakenly target the body’s tissues or cells. This interaction can lead to autoimmune diseases. Unlike normal antibodies that protect against infections, fAABs disrupt normal functions by binding to cell receptors or other proteins, often imitating or blocking natural signals needed for healthy cell functions. This disruption can result in a variety of autoimmune diseases, depending on the target of the autoantibodies and the role of the targeted tissue in the body.

“The presence of fAABs in such a large portion of patients highlights the potential of BC 007 to combat the underlying cause of Long COVID symptoms in a significant group of affected individuals. We are convinced of BC 007’s therapeutic potential and are actively seeking support to prepare for a larger Phase III study,” adds Oliver von Stein. “Our commitment to finding a cure for diseases caused by fAABs remains steadfast, supported by private funding since our inception.”

Versatile Platform Technology Targeting Multiple Medical Conditions
The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

Built on more than two decades of fAAB-research, Berlin Cures has advanced BC 007 into clinical trials. This journey has demonstrated efficacy in Phase I studies with fAAB-positive volunteers and in a Phase IIa trial with heart failure patients, showing significant long-term benefits. Preclinical and clinical results with BC 007 have shown effective and lasting neutralization of fAABs after treatment. Moreover, BC 007 has proven to be safe and well-tolerated. With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

Hashtag: #BerlinCures

The issuer is solely responsible for the content of this announcement.

About Berlin Cures:

The Berlin Cures team has dedicated over two decades to the research of functional autoantibodies (fAABs) and has successfully identified a molecule capable of effectively neutralizing these. Promising preclinical results have been observed for BC 007. It was found effective in fAAB-positive healthy volunteers during the Phase I study and in heart failure patients in a Phase IIa trial, where it demonstrated long-term autoantibody neutralization after a single dose and significant improvement in cardiac function, with no spontaneous disappearance of autoantibodies in untreated patients. Its potential against Long COVID is indicated by lab data generated using sera from Long COVID patients, and four case studies. By tackling the root cause of fAAB-associated diseases with this unique biotechnology, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue at its core.

Since June 2023, Berlin Cures has been absolving a Phase II clinical trial with BC 007 in the indication Long COVID, an acute and escalating global health problem, to obtain meaningful and robust results on efficacy and tolerability of BC 007 with patients suffering from Long COVID.

AIM Vaccine Enters the Period of Explosive Growth in Major Single Products

Leading the Two Golden Tracks of Pneumonia Vaccine and Rabies Vaccines


HONG KONG SAR – Media OutReach Newswire – 4 March 2024 – AIM Vaccine Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the company has made significant progress in the research and development of its Pneumonia vaccine and Rabies vaccine products. The launch of these new products is expected to accelerate, providing significant momentum for the company’s future revenue growth. The Company has initiated Phase II clinical trials for its Tetravalent meningococcal conjugate vaccine (MCV4), while the clinical trials for the Group’s diphtheria, tetanus and acellular pertussis – HIB combined vaccine is also progressing rapidly.

According to the preliminary performance forecast for the 2023 , assuming that the sales revenue remains relatively stable compared to 2022, the company has made significant provisions for impairment of intangible assets and goodwill, as well as increased research and development expenses due to the third-phase clinical trials of its five major core products and the changing landscape of the COVID-19 pandemic. As a result, the performance for the year 2023 is expected to be a loss. However, it is anticipated that with the concentrated launch of several heavyweight new products by the company, AIM Vaccine is poised for a strong comeback

AIM Vaccine is strategically developing its portfolio of Pneumonia vaccine products by continuously innovating and rapidly advancing iterative upgrades through research and development. Among them, the 13-valent pneumonia conjugate vaccine has completed on-site work for Phase III clinical trial and has submitted a pre-application for marketing. the 23-valent pneumonia polysaccharide vaccine has also completed Phase III clinical trial and is expected to apply for marketing registration in 2024. the 20-valent pneumonia conjugate vaccine has submitted a pre-application for clinical trials; while the 24-valent pneumonia conjugate vaccine, which is being simultaneously developed globally for the first time, has completed preclinical research.

According to the classification of the World Health Organization, pneumococcal disease is one of the diseases requiring “very high priority” use of vaccines for prevention. The 13-valent pneumonia conjugate vaccine approved in China only covers those under 6 years old. The market for those over 6 years old is still blank. China Insights Industry Consultancy Limited, an industry consultant, predicts that the market size of this vaccine in China is expected to exceed RMB20 billion by 2030, indicating tremendous market potential. In addition, the estimated penetration rate of the 13-valent pneumonia conjugate vaccine in the approved age group in China is 25.9%, while the penetration rate in the corresponding age group in the United States exceeds 80%, indicating that there is still significant room for growth in the Chinese market. It is estimated that the global underserved demand for the 13-valent pneumonia conjugate vaccines is as high as 180 million doses. However, currently only three companies have been approved to supply them globally. After the launch of its 13-valent pneumonia conjugate vaccine, the Group is expected to become an important supplier in the market.

The Group’s strategic positioning of its rabies vaccine products has also achieved exciting progress. As the second largest supplier of rabies vaccine globally, the Group has expedited the development of iterative rabies series vaccines, in particular: The on-site work of the phase III clinical trial of iterative serum-free rabies vaccine has been completed, and various preparatory work for the new drug application is underway, which is planned to be completed in 2024; The pre-application for clinical trial for the novel-process human diploid rabies vaccine is expected to be submitted in the first half of 2024; 3. the iterative mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

To date, there is no serum-free rabies vaccine approved for launch in the global market. The novel-process human diploid rabies vaccine developed by the Group became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.

Based on the performance forecast and the progress in product development, AIM Vaccine’s investment in research and development is gradually paying off. The company’s revenue and operations are stable and improving, which will help the company better seize market opportunities. At the same time, AIM Vaccine adheres to its development strategy and layout of major single products, large production capacity, and strong commercialization capabilities. Leveraging its top-class vaccine development platform technology and internal research and development team, the company fully meets the market demand for iterative upgraded vaccines. This helps achieve new productive forces in the industry, leads international industry innovation, and contributes to the establishment of a robust public health system and the comprehensive implementation of the Healthy China strategy.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

About AIM Vaccine Co., Ltd.

AIM Vaccine (stock code: 06660) is committed to manufacturing conscientious vaccines and promoting the health of the people. It is the second-largest vaccine group in China and the largest private-sector vaccine group, with a complete industry chain. AIM Vaccine is a leading company in the Chinese vaccine industry and one of the top players in the mRNA vaccine field. As one of the most strictly regulated industries in the country, China has over 40 vaccine production qualifications nationwide. Currently, AIM Vaccine owns four wholly-owned licensed vaccine production companies and three vaccine research institutes. It is one of the only two human vaccine companies in China with strategic resources such as P3 laboratories. AIM Vaccine is also the world’s largest manufacturer of hepatitis B vaccines and the second-largest manufacturer of rabies vaccines globally.

AIM Vaccine has a portfolio of eight commercialized vaccines and 23 vaccines under development, covering the top ten vaccine varieties globally. Its commercialized products have maintained a leading market position for a long time, with sales covering all 31 provinces, municipalities, and autonomous regions in China, reaching over 2,000 district and county-level disease control centers.

ASEAN-South Korea Music Festival 2024 Coming to Laos in November

(Photo: The Star)

The ASEAN-South Korea Music Festival 2024 (2024 ROUND) is set to take place in Laos this November.